Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound inside the lungs could spot deadly clots in ICU patients

NCT ID NCT04047784

Diagnosis Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing whether a special ultrasound scope (EBUS) can diagnose acute pulmonary embolism (a blood clot in the lung) in critically ill patients in the ICU. These patients often cannot undergo standard CT scans because they are too unstable or have kidney problems. The study will enroll 60 intubated adults and compare EBUS findings to CT results when available, and track patient outcomes. If EBUS proves accurate, it could offer a faster, bedside way to diagnose life-threatening clots.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endobronchial ultrasound (EBUS) device
What this could lead to
If successful, EBUS could provide a bedside tool to quickly diagnose dangerous blood clots in the lungs of ICU patients who are too unstable for standard scans.
What could go wrong
This is a small pilot study (60 patients) with no control group, so results may not be definitive. EBUS is not yet proven for this use, and the procedure carries risks like airway bleeding or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2019

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient ≥ 18 years of age. * The patient or patient's surrogate must understand and sign informed consent form (ICF). * Intubated patients in the intensive care unit (ICU) where there is a clinical concern for acute pulmonary embolism or a confirmed diagnosis for acute pulmonary embolism. Exclusion Criteria: * Patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician. * Endotracheal tube size less than 8.0 mm. * Contraindications to lidocaine. Pulmonary Vascular Mapping Substudy: Enrollment for the pulmonary vascular mapping substudy will be based on the following inclusion and exclusion criteria: Inclusion criteria: * Patient ≥ 18 years of age. * The patient or patient's surrogate must understand and sign informed consent form (ICF). * Intubated patients undergoing clinical bronchoscopy, as determined by the treating physician. Exclusion criteria: * Patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician. * Endotracheal tube size less than 8.0 mm. * Contraindications to lidocaine. Retrospective Chart Review: Of the 60 total subjects enrolled in the study, media including images and videos that are previously recorded for 20 patients who underwent a clinical bronchoscopy with EBUS as a part of their standard of care will also be available to our research team without consent from the patient to help supplement the data we obtain from the 20 subjects that are enrolled in the pulmonary vascular mapping substudy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute pulmonary embolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute pulmonary embolism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California, 90095, United States

  • UCLA Medical Center, Santa Monica

    Santa Monica, California, 90404, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.